99 related articles for article (PubMed ID: 24549681)
1. Shift-invariant target in allocation problems.
Mandal S; Biswas A
Stat Med; 2014 Jul; 33(15):2597-611. PubMed ID: 24549681
[TBL] [Abstract][Full Text] [Related]
2. Optimal response-adaptive designs for continuous responses in phase III trials.
Biswas A; Bhattachary R; Zhang L
Biom J; 2007 Dec; 49(6):928-40. PubMed ID: 17722195
[TBL] [Abstract][Full Text] [Related]
3. Covariate-adjusted adaptive designs for continuous responses in a phase III clinical trial: recommendation for practice.
Biswas A; Huang HH; Huang WT
J Biopharm Stat; 2006; 16(2):227-39. PubMed ID: 16584069
[TBL] [Abstract][Full Text] [Related]
4. Multiple-objective response-adaptive repeated measurement designs in clinical trials for binary responses.
Liang Y; Li Y; Wang J; Carriere KC
Stat Med; 2014 Feb; 33(4):607-17. PubMed ID: 24038318
[TBL] [Abstract][Full Text] [Related]
5. Replacement of gabapentin with pregabalin in postherpetic neuralgia therapy.
Ifuku M; Iseki M; Hidaka I; Morita Y; Komatus S; Inada E
Pain Med; 2011 Jul; 12(7):1112-6. PubMed ID: 21692969
[TBL] [Abstract][Full Text] [Related]
6. Response-Adaptive Allocation for Circular Data.
Biswas A; Dutta S; Laha AK; Bakshi PK
J Biopharm Stat; 2015; 25(4):830-42. PubMed ID: 24919034
[TBL] [Abstract][Full Text] [Related]
7. Covariate-adjusted response-adaptive designs for longitudinal treatment responses: PEMF trial revisited.
Biswas A; Park E; Bhattacharya R
Stat Methods Med Res; 2012 Aug; 21(4):379-92. PubMed ID: 20974667
[TBL] [Abstract][Full Text] [Related]
8. The effect of pregabalin on pain-related sleep interference in diabetic peripheral neuropathy or postherpetic neuralgia: a review of nine clinical trials.
Roth T; van Seventer R; Murphy TK
Curr Med Res Opin; 2010 Oct; 26(10):2411-9. PubMed ID: 20812792
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: Open-label, non-comparative, flexible-dose study.
Baron R; Brunnmüller U; Brasser M; May M; Binder A
Eur J Pain; 2008 Oct; 12(7):850-8. PubMed ID: 18242109
[TBL] [Abstract][Full Text] [Related]
10. Sequential urn designs with elimination for comparing K > or =3 treatments.
Coad DS; Ivanova A
Stat Med; 2005 Jul; 24(13):1995-2009. PubMed ID: 15803441
[TBL] [Abstract][Full Text] [Related]
11. A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin.
Zin CS; Nissen LM; O'Callaghan JP; Duffull SB; Smith MT; Moore BJ
J Pain; 2010 May; 11(5):462-71. PubMed ID: 19962354
[TBL] [Abstract][Full Text] [Related]
12. Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief.
Stacey BR; Barrett JA; Whalen E; Phillips KF; Rowbotham MC
J Pain; 2008 Nov; 9(11):1006-17. PubMed ID: 18640074
[TBL] [Abstract][Full Text] [Related]
13. Adaptive biased-coin designs for skewing the allocation proportion in clinical trials with normal responses.
Atkinson AC; Biswas A
Stat Med; 2005 Aug; 24(16):2477-92. PubMed ID: 16007571
[TBL] [Abstract][Full Text] [Related]
14. Time to onset of neuropathic pain reduction: A retrospective analysis of data from nine controlled trials of pregabalin for painful diabetic peripheral neuropathy and postherpetic neuralgia.
Sharma U; Griesing T; Emir B; Young JP
Am J Ther; 2010; 17(6):577-85. PubMed ID: 20393345
[TBL] [Abstract][Full Text] [Related]
15. Optimal response-adaptive randomized designs for multi-armed survival trials.
Sverdlov O; Tymofyeyev Y; Wong WK
Stat Med; 2011 Oct; 30(24):2890-910. PubMed ID: 21823146
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of gabapentin enacarbil in subjects with neuropathic pain associated with postherpetic neuralgia (PXN110748).
Zhang L; Rainka M; Freeman R; Harden RN; Bell CF; Chen C; Graff O; Harding K; Hunter S; Kavanagh S; Laurijssens B; Schwartzbach C; Warren S; McClung C
J Pain; 2013 Jun; 14(6):590-603. PubMed ID: 23602345
[TBL] [Abstract][Full Text] [Related]
17. Cost-utility of pregabalin as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in Belgium.
Chevalier P; Lamotte M; Van Campenhout H; Eyckerman R; Annemans L
J Med Econ; 2013; 16(5):596-605. PubMed ID: 23409950
[TBL] [Abstract][Full Text] [Related]
18. Relationship between pain relief and improvements in patient function/quality of life in patients with painful diabetic peripheral neuropathy or postherpetic neuralgia treated with pregabalin.
Vinik A; Emir B; Cheung R; Whalen E
Clin Ther; 2013 May; 35(5):612-23. PubMed ID: 23541708
[TBL] [Abstract][Full Text] [Related]
19. Clinical practice. Postherpetic neuralgia.
Johnson RW; Rice AS
N Engl J Med; 2014 Oct; 371(16):1526-33. PubMed ID: 25317872
[No Abstract] [Full Text] [Related]
20. Pregabalin: new drug. Very similar to gabapentin.
Prescrire Int; 2005 Dec; 14(80):203-6. PubMed ID: 16397976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
